Barclays raised the firm’s price target on Edwards Lifesciences (EW) to $85 from $80 and keeps an Overweight rating on the shares. The company reported a solid beat on sales and earnings and the Q4 guidance and 2025 commentary should drive continued upward momentum for the stock, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EW:
- Edwards Lifesciences price target lowered to $70 from $73 at Piper Sandler
- Edwards Lifesciences price target lowered to $70 from $71 at Truist
- Edwards Lifesciences price target raised to $63 from $60 at Canaccord
- Edwards Lifesciences price target raised to $78 from $72 at JPMorgan
- Edwards Lifesciences price target lowered to $68 from $73 at Baird